Addex Releases Results For ADX10059 PD-LID At GPCR Drug Discovery Conference

Addex has presented results from studies of its lead clinical candidate, ADX10059, in animal models of parkinson’s disease levodopa induced dyskinesia (PD-LID) at the Discovery on Target GPCR-based Drug Discovery conference in Boston.

Addex disclosed that in a non-human primate model of PD-LID, ADX10059 had a statistically significant impact on dystonia including generalized dystonia, tardive dyskinesia, levodopa non responsive PD syndrome and multiple system atrophy. The company said there is no approved treatment available for PD-LID.

ADX10059 is the first-in-class negative allosteric modulator (NAM) of metabotropic glutamate receptor 5 (mGluR5), a mechanism that is being tested in multiple indications by Addex. It is currently being evaluated in Phase IIb clinical trials for the treatment of gastroesophageal reflux disease (GERD) and to prevent migraine. Separate announcements of data from the two ongoing GERD trials are expected before year-end and early in 2010. The migraine study will report data early in the second quarter of 2010.

ADX10059 demonstrated significant efficacy in well-established preclinical models of PD and PD-LID. These effects in PD and PD-LID were seen at doses and plasma concentrations that have shown efficacy in both clinical and preclinical studies with the compound in other indications. The effects on dystonia also present potential development opportunities for treatment of other types of dystonia.

In the non-human primate MPTP(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) model of PD-LID, all doses of ADX10059 abolished LID during the first hour following L-DOPA administration and a dose response was observed during the second hour, reaching statistical significance for the two higher doses tested.

When tested in the rat model, oral administration of ADX10059 dose-dependently reversed the catalepsy induced by haloperidol in 3 independent experiments.